Regulation & law · 17/09/2002Updated: 10/17/2026 · 1 min read
NIH to Grant Co-Exclusive License for Pseudomonas Aeruginosa Vaccine
Summary
The National Institutes of Health is considering a limited field of use co-exclusive worldwide license for a vaccine against Pseudomonas Aeruginosa, a potential therapeutic application of a chimeric protein developed by Cytovax Biotechnologies Inc.